All News

11 September 2012

Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Human AntibodyAntibodies

10 September 2012

MorphoSys and the University of Melbourne Publish Preclinical Data on the Role of GM-CSF in Inflammatory, Arthritic and Osteoarthritic PainAntibodies

10 September 2012

Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune BalanceAntibodies

8 September 2012

Interim Data From Peregrine’s Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavituximab-Containing ArmsAntibodies

6 September 2012

Clinical Cancer Research Publishes OncoMed Data Demonstrating Anti-Cancer Activity for Anti-DLL4 (Demcizumab) in Pancreatic CancerAntibodies

6 September 2012

ImmunoGen, Inc. Announces Presentation of New IMGN901 Clinical DataAntibodies

5 September 2012

biOasis’s Herceptin(R)-BT2111 Stops Human Breast Cancer Tumor Growth in AnimalsAntibodies

5 September 2012

TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, Ublituximab, in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s LymphomaAntibodies

5 September 2012

Baxter Initiates Phase I Clinical Trial With anti-MIF Antibody in Patients with Solid TumorsAntibodies

5 September 2012

New data for Novartis drug Lucentis confirms long-term efficacy and safety profile and benefits of individualized treatmentAntibodies

28 August 2012

Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn’s DiseaseAntibodies

28 August 2012

FDA Lifts Clinical Hold on Lpath’s iSONEPAntibodies

28 August 2012

Morphotek, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue SarcomaAntibodies

27 August 2012

Genzyme Provides Update on U.S. LEMTRADA FilingAntibodies

27 August 2012

New Data from Phase III EMILIA Study Showed Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Improved Survival of People With HER2-Positive Metastatic Breast CancerAntibodies

24 August 2012

Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell CarcinomaAntibodies

24 August 2012

Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer’s DiseaseAntibodies

23 August 2012

Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid ArthritisAntibodies

22 August 2012

Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD JournalAntibodies

19 August 2012

AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial PlansAntibodies

16 August 2012

Apexigen Announces the Filing of an IND by its Partner, 3SBioAntibodies

15 August 2012

MORPHOTEK OPENS PILOT ANTIBODY MANUFACTURING PLANTAntibodies

11 August 2012

Crucell and Scripps Research Discover and Describe Broad-Spectrum Antibodies Against Influenza B, a Crucial Link in Development of Universal Flu Therapies and VaccineAntibodies

11 August 2012

Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease WorseningAntibodies

11 August 2012

FDA Approves Lucentis (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)Antibodies

9 August 2012

AmorChem invests in a novel cholesterol-lowering biologic product targeting PCSK9Antibodies

9 August 2012

Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic CancerAntibodies

8 August 2012

BTG Announces Data from Phase IIb Study of AZD9773Antibodies

7 August 2012

Pfizer Announces Co-Primary Clinical Endpoints Not Met In Second Phase 3 Bapineuzumab Study In Mild-To-Moderate Alzheimer’s Disease Patients Who Do Not Carry The Apoe4 GenotypeAntibodies

7 August 2012

Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer’s DiseaseAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

GPC3-Targeted Immunotherapy Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Report Package: “Drug the Undruggable” Technologies

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Ustekinumab (Stelara) Biosimilars Pipeline Review